Charge-Engineered Lysozyme Variants for Lung Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for lung infections, particularly those caused by bacteria, are hindered by the emergence of antibiotic resistance and the inability of wild-type lysozyme to function effectively in the presence of anionic biopolymers like DNA, mucin, and alginate, which are abundant in infected lungs, leading to reduced antimicrobial activity and increased inflammatory response.
Innovation Solution
Genetically engineered lysozyme variants with reduced electrostatic charge, achieved through mutation of lysine, arginine, or histidine residues to uncharged or negatively charged amino acids, or by chemical means such as attachment to nanoparticles, exhibit enhanced antimicrobial activity against bacterial, fungal, or viral infections, particularly in the presence of inhibitory anionic biopolymers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If wild-type lysozyme is used to treat lung infections, then antimicrobial activity is provided, but the activity is reduced in the presence of anionic biopolymers like DNA, mucin, and alginate
Solution Approach 1:
The patent applies parameter changes by modifying the electrostatic charge of lysozyme through site-directed mutagenesis. Specifically, basic residues (lysine, arginine, histidine) are mutated to uncharged or negatively charged amino acids, reducing the overall positive charge of the enzyme. This parameter change allows the lysozyme to maintain antimicrobial activity while reducing its interaction with anionic biopolymers that inhibit wild-type lysozyme function in infected lung environments.
2Reliability
If antibiotics are used to treat bacterial infections, then bacterial growth is inhibited, but antibiotic resistance emerges reducing treatment effectiveness
Solution Approach 1:
The patent replaces the chemical mechanism of conventional antibiotics with a different biochemical mechanism using engineered lysozyme. Instead of relying on ribosomal or enzyme targets that accumulate adaptive mutations and resistance elements, the engineered lysozyme acts through cell wall hydrolysis with a modified electrostatic mechanism that is less susceptible to traditional resistance development pathways.
3Reliability
If the electrostatic charge of lysozyme is reduced to overcome inhibition by anionic biopolymers, then activity in infected lung environment is improved, but binding affinity to bacterial cells may be reduced
Solution Approach 1:
The patent applies local quality by making specific localized changes to the lysozyme molecule through site-directed mutagenesis of particular basic residues. Rather than uniformly reducing charge throughout the molecule, specific lysine, arginine, or histidine residues are mutated at strategic positions to reduce overall positive charge while preserving local regions necessary for bacterial cell wall binding and enzymatic activity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These variants demonstrate significantly improved antimicrobial activity, with increased IC50 values for inhibitors like alginate, DNA, and mucin, reducing bacterial burden and inflammatory response in respiratory infections, making them effective therapeutic agents for treating lung infections.
Implementation Method 1
the variant exhibits enhanced antimicrobial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge
Data Source
AI summary
The present invention is a genetically engineered version of a lysozyme protein wherein the engineered enzyme exhibits enhanced antimicrodial activity, relative to the wild type enzyme, as a result of a reduced overall electrostatic charge. Such an enzyme is an attractive therapeutic candidate for treating microbial or viral infections, particularly in cases where the infection results in an accumulation of polyanion inhibitors at the site of infection. Respiratory tract infections are one example of an infection where such an enzyme might be a particularly useful drug.